Jim Cramer's top 10 things to watch in the stock market Thursday

Markets are starting steady as S&P futures are flat and the 10Y Treasury yield is down a couple bps, but investors are rotating away from high-multiple stocks as yields rise. Stock-specific catalysts are mixed: Snowflake surged 24% on blow-away results and guidance, while Broadcom shares fell ~3% after revenue beat but a light near-term guidance offset by an “AI revenue guide” through 2028; HPE is also pressured (-3%) despite earnings/revenue beating consensus and raising next fiscal-year growth. In AI/M&A, Nvidia announced a $12.9B deal to buy Hugging Face, while Boeing headlines add risk via newly uncovered liabilities at Spirit AeroSystems and Moderna was downgraded to sell as optimistic vaccine-trial reactions may be overextended.

Analysis

Higher yields are changing the equity discount-rate regime more than the underlying AI demand story. The market is rewarding names with near-term monetization and punishing anything where value depends on cash flows far out on the curve; that makes AVGO vulnerable even with a strong strategic narrative, because optionality in 2028 does little for this year’s multiple. The same environment is supportive for cash-generative, fee-like businesses such as OKE, where duration is shorter and leverage to a calmer rate path is better.

SNOW’s reaction is the clearest sign that AI spend is broadening beyond chips into software that can actually scale usage. If that holds, the second-order losers are low-differentiation SaaS vendors and server assemblers whose revenue can grow while economics stay thin; HPE/DELL can report good demand but still fail to earn a premium if working-capital intensity and margin mix keep compressing. That also argues for keeping NVDA as the highest-quality AI exposure, with the rest of the hardware stack increasingly looking like a volume trade rather than a compounding story.

On the negative side, BA still has a balance-sheet/operations overhang that gets worse when supplier liabilities become visible, because every extra cash claim reduces flexibility just as fuel and delivery pressures stay noisy. MRNA looks like a classic extrapolation setup: the market is pricing platform success off one encouraging readout, but the scope of the data does not justify that breadth. Contrarian take: the software short trade may be getting crowded, but the bigger near-term mistake is assuming every AI-adjacent name benefits equally; the market is starting to discriminate by duration, margin quality, and proof of recurring demand.

Key Decisions for Investors

• Long NVDA / short AVGO for 1-3 months: express the view that near-term demand visibility and execution quality should outperform long-dated AI optionality; target relative outperformance if AVGO continues to lag on guidance credibility. Falsify if AVGO shows order acceleration or NVDA growth decelerates on the next print.
• Buy SNOW on a pullback or use a 1-2 month call spread: this is the cleanest beneficiary of AI consumption broadening into software. Risk/reward is best if the stock digests part of the gap first; invalidate if usage growth or net retention stalls in the next quarter.
• Short BA on strength for 1-3 months, or buy downside puts into rallies: supplier liability headlines plus higher input costs create a slow-burn FCF risk, not just a sentiment issue. Cover if there is a material delivery or cash-flow inflection, or if new disclosures reduce the liability overhang.
• Long OKE for 3-6 months on any rate-induced dip: fee-based cash flows plus financing support make this a better relative beneficiary than higher-beta energy names. Falsify if long-end yields spike materially or if acquisition integration/leverage metrics deteriorate.
• Pair short MRNA / long MRK for event-driven mean reversion over 4-8 weeks: the market appears to be extrapolating a narrow oncology readthrough into a platform rerate. Exit if additional clinical data broadens the response beyond the original subset.